Wordt geladen...
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical stud...
Bewaard in:
| Gepubliceerd in: | Pharmacol Res |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876767/ https://ncbi.nlm.nih.gov/pubmed/26995304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2016.03.013 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|